| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
Purity: ≥98%
SF2312 is a novel, highly potent and low-nanomolar inhibitor of enolase. SF2312 is a phosphonate antibiotic of unknown mode of action produced by the actinomycete Micromonospora, which is active under anaerobic conditions. Despite being crucial for energy generation in most forms of life, few if any microbial antibiotics specifically inhibit glycolysis.
| Targets |
SF-2312 is a highly potent inhibitor of Enolase (ENO2 and ENO1). The enzymatic inhibition IC₅₀ for SF-2312 against human Enolase 2 (ENO2) is in the low nM range (approximately 10 nM). [1]
|
|---|---|
| ln Vitro |
SF2312 preferentially poisons glioma cells that lack ENO1. In contrast, syngeneic ENO1-rescued D423 cells, which ectopically re-expressed ENO1, only demonstrated proliferation at SF2312 doses greater than 200 μM. The ENO1-deleted D423 glioma cell line was inhibited in its ability to proliferate within the low μM range after two weeks of treatment. restraint. Only ENO1-depleted glioma cells are selectively affected by SF2312 (10 μM), which dose-dependently lowers the conversion of U-13C glucose to 13C lactate [1]. This effect does not occur in ENO1-rescued or other ENO1-intact glioma cells. The actinomycete Micromonospora produces SF2312, which has a broad spectrum of antibacterial action. It is particularly effective against Salmonella and Staphylococcus aureus, but less effective against Escherichia coli and inactive against fungi [1].
SF-2312 potently inhibits the enzymatic activity of Enolase in vitro, with an IC₅₀ in the low nM range. [1] SF-2312 selectively inhibits the proliferation of ENO1-deleted glioma cell lines (D423 and Gli56) in the low µM range, while isogenic ENO1-rescued cells only show inhibition at concentrations above 200 µM. [1] SF-2312 treatment (10 µM) for 72 hours leads to a profound inhibition of glycolysis in ENO1-deleted glioma cells, as evidenced by decreased conversion of ¹³C-glucose to ¹³C-lactate and increased conversion to ¹³C-glycerate. [1] SF-2312 treatment results in a significant increase in the 3-PGA/PEP ratio in ENO1-deleted glioma cells, indicating specific inhibition of Enolase activity within cells. [1] SF-2312 induces apoptosis in ENO1-deleted D423 glioma cells starting at 12.5 µM, while ENO1-rescued controls only show cell death induction at 400 µM. [1] SF-2312 treatment decreases ATP levels and other high-energy phosphates (e.g., phosphocreatine) in ENO1-deleted glioma cells as early as 8 hours after treatment initiation. [1] |
| Enzyme Assay |
Enolase enzymatic activity was measured using two methods: a fluorometric NADH-linked assay and a direct spectrophotometric assay via formation of phosphoenolpyruvate (PEP). For the fluorometric assay, enolase activity was measured via NADH oxidation in a pyruvate kinase-lactate dehydrogenase coupled assay. The assay was conducted in a buffer containing KCl, MgSO₄, triethanolamine, NADH, and ADP, with excess 2-phosphoglycerate (2-PGA), pyruvate kinase, and lactate dehydrogenase. Enolase activity was determined by measuring the oxidation of NADH fluorometrically with excitation at 340 nm and emission at 460 nm. The substrate concentration was 5 mM 2-PGA. Alternatively, enolase activity was measured directly by the appearance of PEP from 2-PGA via absorption at 240 nm, omitting auxiliary reagents. Both assays were conducted in a 96-well plate format. [1]
|
| Cell Assay |
Cell proliferation was assayed using crystal violet staining or by live-cell confluence measurements with an automated imaging system. For crystal violet assays, cells were seeded in 96-well plates, treated, fixed with formalin, stained with crystal violet, and the dye was extracted with acetic acid for absorbance measurement at 595 nm. [1]
Apoptosis was assessed by staining cells with YO-PRO®-1 iodide. Apoptotic cells become permeable to the dye, while live cells are not stained. Total cell number was quantified using Hoechst 33342. Cells were seeded in 96-well plates, treated, stained, and imaged using a high-content screening system. [1] ATP content was measured using a luciferase/luciferin-based assay. The assay reagent was added to cells in 96-well plates, and luminescence was measured. [1] Glycolytic flux was measured using ¹³C isotope tracing. Cells were cultured in glucose-free DMEM supplemented with ¹³C-1 or uniformly labeled ¹³C-glucose. Media metabolites were extracted with methanol, lyophilized, resuspended in D₂O, and analyzed by ¹³C NMR spectroscopy. [1] Cellular thermal shift assays were performed to demonstrate direct binding of SF-2312 to Enolase in intact cells. Cells were treated with the drug, trypsinized, washed, resuspended in PBS, and subjected to a temperature gradient. Cells were then lysed, centrifuged, and the supernatant was analyzed by Western blot. [1] |
| Toxicity/Toxicokinetics |
SF-2312 exhibited selective toxicity to ENO1-deficient glioma cells, but no such effect on ENO1-recovered or intact cells. In ENO1-deficient D423 cells, low µM concentrations were sufficient to inhibit cell proliferation and induce apoptosis, while higher concentrations (above 200 µM) were required for ENO1-recovered cells. [1]
|
| References | |
| Additional Infomation |
SF-2312 is a natural phosphonate antibiotic produced by the actinomycete Micromonospora, initially discovered for its antibacterial activity under anaerobic conditions. Its mechanism of action was previously unknown. [1] SF-2312 is a racemic mixture of cis and trans diastereomers. X-ray crystallography analysis showed that the (S,S)-enantiomer is the active form bound to enolase. [1] SF-2312 may penetrate bacterial membranes via the glucose-6-phosphate transport system, similar to fosfomycin, which may explain its lack of activity against fungi. [1] The phosphonate moiety of SF-2312 makes it less permeable to cells, which limits its development as a therapeutic agent. [1]
|
| Molecular Formula |
C4H8NO6P
|
|---|---|
| Molecular Weight |
197.08322
|
| Exact Mass |
197.009
|
| Elemental Analysis |
C, 24.38; H, 4.09; N, 7.11; O, 48.71; P, 15.72
|
| CAS # |
107729-45-3
|
| Related CAS # |
SF2312 ammonium
|
| PubChem CID |
52913330
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
-2.4
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
248
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ON1C(O)CC(P(=O)(O)O)C1=O
|
| InChi Key |
CGWBGDOPBYWJKZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H8NO6P/c6-3-1-2(12(9,10)11)4(7)5(3)8/h2-3,6,8H,1H2,(H2,9,10,11)
|
| Chemical Name |
(1,5-dihydroxy-2-oxopyrrolidin-3-yl)phosphonic acid
|
| Synonyms |
SF2312; SF 2312; SF-2312
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0741 mL | 25.3704 mL | 50.7408 mL | |
| 5 mM | 1.0148 mL | 5.0741 mL | 10.1482 mL | |
| 10 mM | 0.5074 mL | 2.5370 mL | 5.0741 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 SF2312 is a potent inhibitor of Enolase with mixed competitive and non-competitive kinetics.Nat Chem Biol.2016Dec;12(12):1053-1058. |
|---|
 SF2312 stabilizes Enolase 2 against thermal denaturation.Nat Chem Biol.2016Dec;12(12):1053-1058. |
 SF2312 inhibits Enolase activity and is selectively toxic to ENO1-deleted glioma cells.Nat Chem Biol.2016Dec;12(12):1053-1058. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA